Diagnostics (May 2022)

PBMNCs Treatment in Critical Limb Ischemia and Candidate Biomarkers of Efficacy

  • Matilde Zamboni,
  • Massimo Pedriali,
  • Luca Ferretto,
  • Sabrina Scian,
  • Francesca Ghirardini,
  • Riccardo Bozza,
  • Romeo Martini,
  • Sandro Irsara

DOI
https://doi.org/10.3390/diagnostics12051137
Journal volume & issue
Vol. 12, no. 5
p. 1137

Abstract

Read online

When in critical limb ischemia (CLI) the healing process aborts or does not follow an orderly and timely sequence, a chronic vascular wound develops. The latter is major problem today, as their epidemiology is continuously increasing due to the aging population and a growth in the incidence of the underlying diseases. In the US, the mean annualized prevalence of necrotic wounds due to the fact of CLI is 1.33% (95% CI, 1.32–1.34%), and the cost of dressings alone has been estimated at USD 5 billion per year from healthcare budgets. A promising cell treatment in wound healing is the local injection of peripheral blood mononuclear cells (PBMNCs). The treatment is aimed to induce angiogenesis as well to switch inflammatory macrophages, called the M1 phenotype, into anti-inflammatory macrophages, called M2, a phenotype devoted to tissue repair. This mechanism is called polarization and is a critical step for the healing of all human tissues. Regarding the clinical efficacy of PBMNCs, the level of evidence is still low, and a considerable effort is necessary for completing the translational process toward the patient bed site. From this point of view, it is crucial to identify some candidate biomarkers to detect the switching process from M1 to M2 in response to the cell treatment.

Keywords